The Asia Pacific Multiple Myeloma Market would witness market growth of 10.8% CAGR during the forecast period (2023-2029).
Diagnosing tumor-related abnormalities discovered through screening methods like radiography is the first step in the therapy procedures for myeloma. Radiotherapy is the first step in treating malignancies since it is a localized method that only affects the area surrounding the tumor. Radiological techniques are typically recommended as therapy choices at the asymptomatic stage of the condition. They are likewise utilized to treat pain brought on by bone deterioration in the latter stages.
Therefore, every cancer treatment must include radiotherapy. Recent developments in radiotherapy, such as its capacity to turn a circumscribed tumor into an in-situ vaccination, have increased the therapy's therapeutic window in several instances. In the treatment of multiple myeloma, radiotherapy has no viable substitute. With the disease's increasing incidence, it is therefore anticipated that the use of this method in multiple myeloma therapy will increase.
Southeast Asian countries are seeing a sharp rise in lymphoma prevalence in the region. The world's highest age-standardized rates of multiple myeloma (MM) incidence are also observed in Australia and its neighboring nations. In Australia, blood cancer affects 60,000 people. Similarly, other countries are also seeing an increase in the prevalence of hematopoietic malignancies. Leukemia, for instance, is now China's ninth-leading cancer-related cause of death. Blood cancer patients make up the third-highest percentage of patients worldwide in India. As a result, the demand for treatment methods in the region has risen due to the increased initiatives taken by different governmental and non-governmental groups in managing the illness prevalence.
The China market dominated the Asia Pacific Multiple Myeloma Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $2,754.3 Million by 2029. The Japan market is estimated to grow a CAGR of 10.2% during (2023 - 2029). Additionally, The India market would experience a CAGR of 11.5% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals, Clinics, and Others. Based on Disease Type, the market is segmented into Active Multiple Myeloma and Smoldering Multiple Myeloma. Based on Drug Type, the market is segmented into Protease Inhibitors, Monoclonal Antibody, Chemotherapy and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Multiple Myeloma Market is Projected to reach USD 37.5 Billion by 2029, at a CAGR of 9.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Bristol Myers Squibb Company, Amgen, Inc., AbbVie, Inc., Sanofi S.A., Johnson & Johnson, Baxter International, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
By Disease Type
- Active Multiple Myeloma
- Smoldering Multiple Myeloma
By Drug Type
- Protease Inhibitors
- Monoclonal Antibody
- Chemotherapy
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Bristol Myers Squibb Company
- Amgen, Inc.
- AbbVie, Inc.
- Sanofi S.A.
- Johnson & Johnson
- Baxter International, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Multiple Myeloma Market, by End User
1.4.2 Asia Pacific Multiple Myeloma Market, by Disease Type
1.4.3 Asia Pacific Multiple Myeloma Market, by Drug Type
1.4.4 Asia Pacific Multiple Myeloma Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Asia Pacific Multiple Myeloma Market by End User
4.1 Asia Pacific Hospitals Market by Country
4.2 Asia Pacific Clinics Market by Country
4.3 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Multiple Myeloma Market by Disease Type
5.1 Asia Pacific Active Multiple Myeloma Market by Country
5.2 Asia Pacific Smoldering Multiple Myeloma Market by Country
Chapter 6. Asia Pacific Multiple Myeloma Market by Drug Type
6.1 Asia Pacific Protease Inhibitors Market by Country
6.2 Asia Pacific Monoclonal Antibody Market by Country
6.3 Asia Pacific Chemotherapy Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Multiple Myeloma Market by Country
7.1 China Multiple Myeloma Market
7.1.1 China Multiple Myeloma Market by End User
7.1.2 China Multiple Myeloma Market by Disease Type
7.1.3 China Multiple Myeloma Market by Drug Type
7.2 Japan Multiple Myeloma Market
7.2.1 Japan Multiple Myeloma Market by End User
7.2.2 Japan Multiple Myeloma Market by Disease Type
7.2.3 Japan Multiple Myeloma Market by Drug Type
7.3 India Multiple Myeloma Market
7.3.1 India Multiple Myeloma Market by End User
7.3.2 India Multiple Myeloma Market by Disease Type
7.3.3 India Multiple Myeloma Market by Drug Type
7.4 South Korea Multiple Myeloma Market
7.4.1 South Korea Multiple Myeloma Market by End User
7.4.2 South Korea Multiple Myeloma Market by Disease Type
7.4.3 South Korea Multiple Myeloma Market by Drug Type
7.5 Singapore Multiple Myeloma Market
7.5.1 Singapore Multiple Myeloma Market by End User
7.5.2 Singapore Multiple Myeloma Market by Disease Type
7.5.3 Singapore Multiple Myeloma Market by Drug Type
7.6 Malaysia Multiple Myeloma Market
7.6.1 Malaysia Multiple Myeloma Market by End User
7.6.2 Malaysia Multiple Myeloma Market by Disease Type
7.6.3 Malaysia Multiple Myeloma Market by Drug Type
7.7 Rest of Asia Pacific Multiple Myeloma Market
7.7.1 Rest of Asia Pacific Multiple Myeloma Market by End User
7.7.2 Rest of Asia Pacific Multiple Myeloma Market by Disease Type
7.7.3 Rest of Asia Pacific Multiple Myeloma Market by Drug Type
Chapter 8. Company Profiles
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental &Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Trials and Approvals:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Product Launches and Product Expansions:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.4 Amgen, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.4.5.2 Acquisition and Mergers:
8.5 AbbVie, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Baxter International, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Product Launches and Product Expansions:
8.8 Pfizer, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional & Segmental Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.9 Bristol Myers Squibb Company
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Trials and Approvals:
8.9.5.2 Acquisition and Mergers:
8.10. Takeda Pharmaceutical Company Limited
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
TABLE 1 Asia Pacific Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Multiple Myeloma Market
TABLE 4 Product Launches And Product Expansions– Multiple Myeloma Market
TABLE 5 Acquisition and Mergers– Multiple Myeloma Market
TABLE 6 Trials and approvals – Multiple Myeloma Market
TABLE 7 Asia Pacific Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 9 Asia Pacific Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Hospitals Market by Country, 2023 - 2029, USD Million
TABLE 11 Asia Pacific Clinics Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Clinics Market by Country, 2023 - 2029, USD Million
TABLE 13 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 15 Asia Pacific Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 17 Asia Pacific Active Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Active Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 19 Asia Pacific Smoldering Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Smoldering Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 21 Asia Pacific Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 23 Asia Pacific Protease Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Protease Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 25 Asia Pacific Monoclonal Antibody Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Monoclonal Antibody Market by Country, 2023 - 2029, USD Million
TABLE 27 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 28 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 29 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 30 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 31 Asia Pacific Multiple Myeloma Market by Country, 2019 - 2022, USD Million
TABLE 32 Asia Pacific Multiple Myeloma Market by Country, 2023 - 2029, USD Million
TABLE 33 China Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 34 China Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 35 China Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 36 China Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 37 China Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 38 China Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 39 China Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 40 China Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 41 Japan Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 42 Japan Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 43 Japan Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 44 Japan Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 45 Japan Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 46 Japan Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 47 Japan Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 48 Japan Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 49 India Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 50 India Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 51 India Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 52 India Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 53 India Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 54 India Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 55 India Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 56 India Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 57 South Korea Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 58 South Korea Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 59 South Korea Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 60 South Korea Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 61 South Korea Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 62 South Korea Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 63 South Korea Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 64 South Korea Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 65 Singapore Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 66 Singapore Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 67 Singapore Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 68 Singapore Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 69 Singapore Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 70 Singapore Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 71 Singapore Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 72 Singapore Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 73 Malaysia Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 74 Malaysia Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 75 Malaysia Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 76 Malaysia Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 77 Malaysia Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 78 Malaysia Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 79 Malaysia Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 80 Malaysia Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 81 Rest of Asia Pacific Multiple Myeloma Market, 2019 - 2022, USD Million
TABLE 82 Rest of Asia Pacific Multiple Myeloma Market, 2023 - 2029, USD Million
TABLE 83 Rest of Asia Pacific Multiple Myeloma Market by End User, 2019 - 2022, USD Million
TABLE 84 Rest of Asia Pacific Multiple Myeloma Market by End User, 2023 - 2029, USD Million
TABLE 85 Rest of Asia Pacific Multiple Myeloma Market by Disease Type, 2019 - 2022, USD Million
TABLE 86 Rest of Asia Pacific Multiple Myeloma Market by Disease Type, 2023 - 2029, USD Million
TABLE 87 Rest of Asia Pacific Multiple Myeloma Market by Drug Type, 2019 - 2022, USD Million
TABLE 88 Rest of Asia Pacific Multiple Myeloma Market by Drug Type, 2023 - 2029, USD Million
TABLE 89 Key information –Johnson & Johnson
TABLE 90 Key Information – Novartis AG
TABLE 91 Key Information – Sanofi S.A.
TABLE 92 Key Information – Amgen, Inc.
TABLE 93 Key information – AbbVie, Inc.
TABLE 94 Key Information – Baxter International, Inc.
TABLE 95 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 96 Key Information – Pfizer, Inc.
TABLE 97 Key Information – Bristol Myers Squibb Company
TABLE 98 Key Information – Takeda Pharmaceutical Company Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 SWOT analysis: Johnson & Johnson
FIG 5 Recent strategies and developments: Novartis AG
FIG 6 Recent strategies and developments: Sanofi S.A.